Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Warrant Indenture

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 29, 2023 10:44am

195 Views

Post# 35609757

RE:RE:RE:RE:RE:RE:Warrant Indenture

The warrants were attached to the purchase of the underlying stock and the warrants have no inherent value other than giving the older the right to purchase the stock at US$2.81 per share. Since the warrants have no inherent value article 5.1 provides that ONCY can purchase the warrants for as little as US$0.01 per warrant, unless the holder decides to convert the warrants into the stock equity at anytime before ONCY decides to exercise its option under 5.1. So the strategy of selling the underlying stock and just holding the warrants, as had been past practice, appears to be now foiled by 5.1.

<< Previous

Bullboard Posts

Next >>

Here are three global stocks you should watch